Advocates on Steps of Congress 2013
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #624 | Sept. 18, 2015  

New Topics Added to Our Website

laptopWe recently added archived content from past issues of "Scleroderma Voice" magazine's "On Call" and "What's Up Doc?" columns on our website. These articles cover various topics and concerns that are common for people living with scleroderma.

Some of the topics include:

To view these and other past topics, click here >>

STAR Clinical Trial Now Enrolling Patients

If you (or someone you know) have impaired function of the hands and Raynaud Phenomenon due to scleroderma, you may be interested in the STAR clinical trial. The STAR clinical trial is designed to study the use of a patient’s own Adipose-Derived Regenerative Cells (ADRCs), prepared using the investigational Celution® Device, in the treatment of scleroderma affecting the hands and fingers. The study will be conducted in patients who are currently on medical therapy and still have impaired hand function and Raynaud’s phenomena. The STAR clinical trial will enroll 80 patients in multiple centers in the United States. 

Dinesh Khanna, M.D., M.S., Director of University of Michigan Scleroderma Program and principal investigator of the STAR trial shared his enthusiasm for hand management in scleroderma, that affects over 90 percent of patients with scleroderma. Hand symptoms are the leading cause of disability in this patient population, more disabling than rheumatoid arthritis, and severely negatively impact quality of life and work productivity. This study addresses this unmet need.  Details of the study can also be found on clinicaltrials.gov.

For more information, please visit www.startrial-us.com.

Additional Reading

Scleroderma Therapy Benefit Sustained at One Year Follow-Up


Biotechnology Firm Receives NIH Grant Support for Fibrosis Therapy

lab researcher imagePRESS RELEASE

NEW YORK, NY. September 9, 2015 – iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biopharmaceutical products, announced the award of a grant to fund further development of its proprietary therapeutic product for treatment of fibrotic diseases from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under its Small Business Technology Transfer (STTR) program. The Fast-Track award will support the work of principal investigators Carol Feghali-Bostwick, Ph.D., of The Medical University of South Carolina (MUSC) and Hal Padgett, Ph.D., of Novici Biotech LLC (Novici) and their research teams. The funded project is entitled, “Peptide Based Therapy for Lung Fibrosis.” The commercial sponsor of the program is iBio, Inc.

Dr. Feghali-Bostwick is a member of the Scleroderma Foundation's Board of Directors.

Read the full press release here >>

Video: Don't Ignore Your Check Engine Light

Video: Don't Ignore Your Check Engine Light
It is easy for caregivers to focus on their loved ones living with scleroderma and to ignore their own physical and emotional needs. Dr. Ginny Maril presented this session at  the 2015 National Patient Education Conference, which focused on the caregiving experience and highlights the importance of self-care while providing care for another. Learn to identify personal strengths and challenges of your caregiving situations and what can be done to maintain your own caregiving engines.

Watch the full session video now >>

Donate Button
Quick Links
Advocacy
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Store
Home
facebook_32.png
twitter_32.png
Youtube_32x32.png

Actelion current web size
Bayer 2015 gold and platinum Sponsor
Gilead Silver Conference Sponsor
United Therapeutics corporate sponsor.jpg

 

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2017 All rights reserved.